Tag Archives: technology

Hot Investor Mandate: Europe-Based Life Sciences Focused VC Builds and Invests in Therapeutics Companies Across Oncology, Rare Diseases, and More

19 May

A life sciences-focused venture capital firm with offices in Europe focuses on disruptive early-stage life sciences companies and invests primarily in therapeutics. The firm is actively investing through its latest fund and has built a portfolio of multiple startups through both direct investments and company creation initiatives. The firm invests predominantly in Europe, with a strong emphasis on opportunities in Western Europe. 
 
The firm invests primarily in therapeutics and does not currently focus on medical devices, diagnostics, or digital health. The firm is modality-agnostic and evaluates a broad range of therapeutic approaches. Areas of strongest interest include oncology, immuno-oncology, rare and orphan diseases, infectious diseases, and immunology. The firm typically invests from preclinical through early clinical stages and focuses on opportunities with the potential to become first- or best-in-class therapies. 
 
From a company and management team perspective, the firm is open to working with both experienced operators and first-time entrepreneurs and has supported several companies led by first-time CEOs. The firm places strong emphasis on diversity in leadership and maintains a hands-on investment approach, actively mentoring and supporting portfolio companies. The firm is open to acting as either a lead investor or co-investor and works closely with scientific founders, academic institutions, and syndicate partners to help companies scale and mature. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Multi-Stage VC Firm With Ties to Global Financial Service Group Seeks Therapeutics and Medtech Addressing Unmet Medical Needs

19 May

A long-established venture capital firm based in Asia is affiliated with one of the world’s largest financial services groups. The firm invests across multiple sectors, including life sciences, and has the flexibility to deploy multi-million-dollar investments depending on the opportunity. The firm evaluates opportunities globally and is actively seeking new international investments. 

Within life sciences, the firm focuses on therapeutics and medical technologies that address significant unmet medical needs relevant to the firm’s domestic market. The firm is particularly interested in companies with clear partnership strategies involving pharmaceutical or healthcare organizations, including licensing, co-development, and strategic investment structures. The firm evaluates a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated products. The firm primarily targets programs in Phase I clinical development but may also consider opportunities approaching clinical entry within approximately one year. Areas of interest include oncology, orphan diseases, and other high unmet need indications. 

From an investment structure perspective, the firm prefers to co-invest alongside established institutional investors in opportunities outside its domestic market. As a result, the firm strongly prefers companies with a credible lead investor or an existing institutional syndicate already in place. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Mastering the Hybrid Hustle: Right Partnering Strategies at Convention Week

19 May

By Caitlin Dolegowski, Program Director, LSN

Partnering conferences are a vital catalyst in an early-stage company’s journey toward securing capital and achieving milestone fundraising goals.

To help you get the absolute most bang for your buck during San Diego Convention Week, here are the top 8 strategies to maximize your ROI on the partnering meetings.

  1. Book Your Registration and Travel Early

Beyond the financial perks, registering early ensures that you are among the very first attendees to gain access to the Partnering system when it opens. In the world of fundraising, the early bird gets the open calendar slot before an investor’s schedule is completely booked.

  1. Perfect Your Partnering Profile Before Sending a Single Message

Once your partnering login hits your inbox, don’t rush straight to messaging. First, meticulously fill out your company profile, detail your tech, and upload your marketing materials (pitch deck and executive summary).

Investors will vet your profile page before hitting “Accept” on a meeting request; an incomplete profile is an automatic decline.

  1. Treat Your Meeting Requests Like a High-Value Pitch

When you begin reaching out to the hundreds of investors, your message needs to be crisp and compelling. Investors want to see specific data points right away. Ensure your meeting requests concisely address:

  • The Hook: Introduce yourself and your company.
  • The Tech: Clearly explain the product/platform.
  • The Market: What critical unmet medical need does it address?
  • The Edge: What does the competition look like, and why are you better?
  • The Traction: Major landmarks, IP status, or clinical achievements to date.
  • The Ask: Current financing needs and exactly how the capital will be used.
  1. Aggressively Fill Your Calendar

Fundraising is a numbers game. Use the partnering system’s advanced filter functions to map out investors who strictly match your company’s sector, indication, and fundraising size. Remember: Most investors will not contact you proactively. You must drive the outreach.

  1. Skip the Morning Rush: Grab Your Badge Early

Most conferences allow you to pick your event badge early. Keep an eye out for the early registration announcements. Picking up your badge a day early allows you to beat the morning lines, scope out the venue, and map your routes between partnering tables and panels so you don’t waste a single minute.

  1. There Are No Breaks in Fundraising

The in-person day in San Diego is an immersive networking marathon. Socializing over breakfast, lunch, and during the evening cocktail reception is just as critical as your scheduled partnering slots. Keep your elevator pitch polished, have your digital business cards or QR codes ready, and be prepared to network with everyone around you. You never know who you might sit next to at lunch.

  1. Be Flexible and Consider All Meeting Types

If an investor turns down a formal meeting request due to a scheduling conflict, do not give up. Use the flexibility of the multiple partnering days to find a slot. Even if a mutual window can’t be found within the conference dates, use the platform to pivot and pitch an ad-hoc meeting via Zoom or a coffee chat outside the formal boundaries.

  1. Network Peer-to-Peer

While investors are the primary target, remember the immense value of talking to fellow founders, CEOs, and service providers. Building a network of peers allows you to share fundraising intelligence, compare notes on active investors, and discover trusted vendors.

Think Big: Build a Full-Year Partnering Runway

Because fundraising is a continuous effort, looking at a single event in isolation can leave gaps in your capital pipeline. LSN hosts five RESI conferences a year globally, feeding into an internal database tracking over 10,000 early-stage life science investors across Venture Capital, Family Offices, Angels, and Corporate Venture arms.

To maintain unstoppable momentum from summer into fall, look into options like the RESI San Diego & RESI Boston Bundle, which locks in your 5-Day Hybrid passes for both the June San Diego and September Boston events. Plan your milestones around the RESI calendar, start your outreach early, and put your best foot forward this June!

Register for RESI San Diego

Merck, Servier & Meiji Pharma Leaders Share Pharma BD Insights Ahead of RESI San Diego & Convention Week

19 May

By Sougato Das, President and COO, LSN

Sougato-DasAs partnering activity ramps up ahead of convention week in San Diego, early-stage life science companies are preparing for a critical week of fundraising, licensing, and strategic business development. To help companies better understand how large pharmaceutical companies evaluate new opportunities, Life Science Nation is hosting a webinar featuring leaders from Merck, Servier, and Meiji Pharma USA.

The webinar, Large Pharma BD & Investment: Merck, Servier & Meiji Pharma Prep You for RESI & Convention, will take place on June 2, 2026 at 1:00 PM ET and will be moderated by Sougato Das.

Carla-Bauer
Carla Bauer
Director, Search and Evaluation, BD & Licensing
Merck
Irene Blat
Irene Blat, PhD
Head of External Innovation, NA
Servier
Sho-Takahata
Sho Takahata
Senior Director, Venture Investment
Meiji Pharma USA

The discussion will explore how pharma companies source and evaluate external innovation, what teams look for during initial meetings, how internal screening processes work, and what makes a company stand out for continued engagement. Topics will also include licensing, R&D partnerships, strategic investment, platform collaborations, and practical tips for improving partnering conversations during convention week.

For companies preparing for RESI San Diego and broader convention week activity, the webinar offers an opportunity to hear directly from pharma business development and investment leaders before arriving in San Diego.

RESI San Diego begins June 22 with an in-person conference day followed by four days of virtual partnering on June 23–24 and June 29–30, connecting early-stage companies with active investors, pharma scouts, strategic partners, and global healthcare stakeholders.

Sign Up for the Webinar

Hot Investor Mandate: Large Family Enterprise-Backed Investment Firm Seeks Next-Generation Therapeutics, Medtech, and AI-Enabled Technologies Across the Globe

12 May

A recently established investment firm based in Asia and backed by a large industrial family enterprise. The firm manages substantial capital and focuses on early-stage opportunities across life sciences and healthcare. The firm typically invests from Seed through Series B and evaluates opportunities globally. In addition to capital investment, the firm is interested in supporting international companies seeking expansion opportunities into the China market.  

The firm’s investment activity is weighted primarily toward therapeutics, while also maintaining interest in diagnostics, medical technology, and AI-enabled healthcare solutions. Within therapeutics, the firm prioritizes highly innovative, next-generation approaches rather than incremental improvements. Areas of interest include advanced drug delivery technologies for mRNA and gene-editing therapies, particularly non-traditional delivery systems and platforms capable of targeting difficult tissues such as the brain. The firm also evaluates extracellular delivery technologies and next-generation cell therapy approaches designed to improve scalability, manufacturability, and cost efficiency. Modalities of interest include TCR-based platforms, NK cell technologies, and macrophage-targeting approaches. The firm is broadly indication-agnostic and is open to technically complex programs addressing major unmet medical needs.  

The firm does not impose strict requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: US-Based Early-Stage Fund Invests Through Pre-Seed to Series A Rounds in Digital Health and AI-Driven Solutions  

12 May

An early-stage venture capital based in the United States focuses on digital health and AI-enabled healthcare technologies designed to shift healthcare from reactive treatment toward prevention, early diagnostics, and long-term disease management. The firm invests across Pre-Seed through Series A stages using both equity and SAFE structures, with typical check sizes ranging from approximately $200K to $2M. Geographically, the firm focuses on health technology companies expanding into the U.S. market, with particular interest in companies operating on the U.S. East Coast and internationally connected healthcare startups. The firm provides hands-on go-to-market support through a broad healthcare network that assists portfolio companies with U.S. commercialization and market-entry strategy.  

The firm is interested in a wide range of digital health and AI-driven healthcare solutions. Core thematic interests include mental health and well-being, women’s health and femtech, chronic disease management, musculoskeletal health, and senior care. The firm also actively evaluates AI-powered diagnostics and clinical decision-support technologies, behavior change and patient engagement platforms, remote patient monitoring solutions with predictive capabilities, prevention and early-detection technologies, and clinically validated digital therapeutics.  

From a company and management team perspective, the firm does not impose strict requirements regarding company structure or leadership composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Asia-Headquartered Multi-Stage VC Firm Actively Seeking Cross-Border  Investment Opportunities in Therapeutics and Digital Health  

12 May

 
A large multi-stage venture capital and private equity firm manages substantial assets across multiple strategies. The firm recently established a dedicated life sciences investment vehicle focused on global venture, growth-stage, and co-investment opportunities. The strategy operates in partnership with major international healthcare and investment organizations to support long-term value creation and commercialization.  

The firm invests broadly across life sciences while expanding its focus into digital healthcare and bio-IT convergence. The strongest areas of interest remain within therapeutics, particularly antibody-drug conjugates (ADC), targeted protein degradation (TPD), and cell and gene therapy. Key therapeutic areas include oncology, metabolic disorders, immunology, and neurology. The firm is also actively evaluating opportunities in AI-enabled healthcare, medical data infrastructure, synthetic biology, next-generation diagnostics, and wearable technologies.  

From a company and management team perspective, the firm prioritizes teams with strong scientific and technical expertise. The investment team includes professionals with R&D and clinical development backgrounds who conduct in-depth technical evaluations. Following investment, the firm leverages strategic global partnerships and industry networks to support commercialization, business development, and technology transfer from academic and research institutions. The firm is particularly interested in companies with strong expansion potential or opportunities positioned for strategic or early exit outcomes. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com